Report Detail

Pharma & Healthcare Global Oral Vaccine for Human Supply, Demand and Key Producers, 2023-2029

  • RnM4526881
  • |
  • 03 April, 2023
  • |
  • Global
  • |
  • 124 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

The global Oral Vaccine for Human market size is expected to reach $ 3783.3 million by 2029, rising at a market growth of 5.4% CAGR during the forecast period (2023-2029).
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection. 
This report studies the global Oral Vaccine for Human production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oral Vaccine for Human, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oral Vaccine for Human that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oral Vaccine for Human total production and demand, 2018-2029, (K Units)
Global Oral Vaccine for Human total production value, 2018-2029, (USD Million)
Global Oral Vaccine for Human production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Oral Vaccine for Human consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Oral Vaccine for Human domestic production, consumption, key domestic manufacturers and share
Global Oral Vaccine for Human production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Oral Vaccine for Human production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Oral Vaccine for Human production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Oral Vaccine for Human market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oral Vaccine for Human market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Oral Vaccine for Human Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Oral Vaccine for Human Market, Segmentation by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Global Oral Vaccine for Human Market, Segmentation by Application
Public
Private
Companies Profiled:
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Key Questions Answered
1. How big is the global Oral Vaccine for Human market?
2. What is the demand of the global Oral Vaccine for Human market?
3. What is the year over year growth of the global Oral Vaccine for Human market?
4. What is the production and production value of the global Oral Vaccine for Human market?
5. Who are the key producers in the global Oral Vaccine for Human market?
6. What are the growth factors driving the market demand?


1 Supply Summary

  • 1.1 Oral Vaccine for Human Introduction
  • 1.2 World Oral Vaccine for Human Supply & Forecast
    • 1.2.1 World Oral Vaccine for Human Production Value (2018 & 2022 & 2029)
    • 1.2.2 World Oral Vaccine for Human Production (2018-2029)
    • 1.2.3 World Oral Vaccine for Human Pricing Trends (2018-2029)
  • 1.3 World Oral Vaccine for Human Production by Region (Based on Production Site)
    • 1.3.1 World Oral Vaccine for Human Production Value by Region (2018-2029)
    • 1.3.2 World Oral Vaccine for Human Production by Region (2018-2029)
    • 1.3.3 World Oral Vaccine for Human Average Price by Region (2018-2029)
    • 1.3.4 North America Oral Vaccine for Human Production (2018-2029)
    • 1.3.5 Europe Oral Vaccine for Human Production (2018-2029)
    • 1.3.6 China Oral Vaccine for Human Production (2018-2029)
    • 1.3.7 Japan Oral Vaccine for Human Production (2018-2029)
  • 1.4 Market Drivers, Restraints and Trends
    • 1.4.1 Oral Vaccine for Human Market Drivers
    • 1.4.2 Factors Affecting Demand
    • 1.4.3 Oral Vaccine for Human Major Market Trends
  • 1.5 Influence of COVID-19 and Russia-Ukraine War
    • 1.5.1 Influence of COVID-19
    • 1.5.2 Influence of Russia-Ukraine War

2 Demand Summary

  • 2.1 World Oral Vaccine for Human Demand (2018-2029)
  • 2.2 World Oral Vaccine for Human Consumption by Region
    • 2.2.1 World Oral Vaccine for Human Consumption by Region (2018-2023)
    • 2.2.2 World Oral Vaccine for Human Consumption Forecast by Region (2024-2029)
  • 2.3 United States Oral Vaccine for Human Consumption (2018-2029)
  • 2.4 China Oral Vaccine for Human Consumption (2018-2029)
  • 2.5 Europe Oral Vaccine for Human Consumption (2018-2029)
  • 2.6 Japan Oral Vaccine for Human Consumption (2018-2029)
  • 2.7 South Korea Oral Vaccine for Human Consumption (2018-2029)
  • 2.8 ASEAN Oral Vaccine for Human Consumption (2018-2029)
  • 2.9 India Oral Vaccine for Human Consumption (2018-2029)

3 World Oral Vaccine for Human Manufacturers Competitive Analysis

  • 3.1 World Oral Vaccine for Human Production Value by Manufacturer (2018-2023)
  • 3.2 World Oral Vaccine for Human Production by Manufacturer (2018-2023)
  • 3.3 World Oral Vaccine for Human Average Price by Manufacturer (2018-2023)
  • 3.4 Oral Vaccine for Human Company Evaluation Quadrant
  • 3.5 Industry Rank and Concentration Rate (CR)
    • 3.5.1 Global Oral Vaccine for Human Industry Rank of Major Manufacturers
    • 3.5.2 Global Concentration Ratios (CR4) for Oral Vaccine for Human in 2022
    • 3.5.3 Global Concentration Ratios (CR8) for Oral Vaccine for Human in 2022
  • 3.6 Oral Vaccine for Human Market: Overall Company Footprint Analysis
    • 3.6.1 Oral Vaccine for Human Market: Region Footprint
    • 3.6.2 Oral Vaccine for Human Market: Company Product Type Footprint
    • 3.6.3 Oral Vaccine for Human Market: Company Product Application Footprint
  • 3.7 Competitive Environment
    • 3.7.1 Historical Structure of the Industry
    • 3.7.2 Barriers of Market Entry
    • 3.7.3 Factors of Competition
  • 3.8 New Entrant and Capacity Expansion Plans
  • 3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World

  • 4.1 United States VS China: Oral Vaccine for Human Production Value Comparison
    • 4.1.1 United States VS China: Oral Vaccine for Human Production Value Comparison (2018 & 2022 & 2029)
    • 4.1.2 United States VS China: Oral Vaccine for Human Production Value Market Share Comparison (2018 & 2022 & 2029)
  • 4.2 United States VS China: Oral Vaccine for Human Production Comparison
    • 4.2.1 United States VS China: Oral Vaccine for Human Production Comparison (2018 & 2022 & 2029)
    • 4.2.2 United States VS China: Oral Vaccine for Human Production Market Share Comparison (2018 & 2022 & 2029)
  • 4.3 United States VS China: Oral Vaccine for Human Consumption Comparison
    • 4.3.1 United States VS China: Oral Vaccine for Human Consumption Comparison (2018 & 2022 & 2029)
    • 4.3.2 United States VS China: Oral Vaccine for Human Consumption Market Share Comparison (2018 & 2022 & 2029)
  • 4.4 United States Based Oral Vaccine for Human Manufacturers and Market Share, 2018-2023
    • 4.4.1 United States Based Oral Vaccine for Human Manufacturers, Headquarters and Production Site (States, Country)
    • 4.4.2 United States Based Manufacturers Oral Vaccine for Human Production Value (2018-2023)
    • 4.4.3 United States Based Manufacturers Oral Vaccine for Human Production (2018-2023)
  • 4.5 China Based Oral Vaccine for Human Manufacturers and Market Share
    • 4.5.1 China Based Oral Vaccine for Human Manufacturers, Headquarters and Production Site (Province, Country)
    • 4.5.2 China Based Manufacturers Oral Vaccine for Human Production Value (2018-2023)
    • 4.5.3 China Based Manufacturers Oral Vaccine for Human Production (2018-2023)
  • 4.6 Rest of World Based Oral Vaccine for Human Manufacturers and Market Share, 2018-2023
    • 4.6.1 Rest of World Based Oral Vaccine for Human Manufacturers, Headquarters and Production Site (State, Country)
    • 4.6.2 Rest of World Based Manufacturers Oral Vaccine for Human Production Value (2018-2023)
    • 4.6.3 Rest of World Based Manufacturers Oral Vaccine for Human Production (2018-2023)

5 Market Analysis by Type

  • 5.1 World Oral Vaccine for Human Market Size Overview by Type: 2018 VS 2022 VS 2029
  • 5.2 Segment Introduction by Type
    • 5.2.1 Rotavirus Vaccine
    • 5.2.2 Cholera Vaccine
    • 5.2.3 Oral Polio Vaccine
    • 5.2.4 Other
  • 5.3 Market Segment by Type
    • 5.3.1 World Oral Vaccine for Human Production by Type (2018-2029)
    • 5.3.2 World Oral Vaccine for Human Production Value by Type (2018-2029)
    • 5.3.3 World Oral Vaccine for Human Average Price by Type (2018-2029)

6 Market Analysis by Application

  • 6.1 World Oral Vaccine for Human Market Size Overview by Application: 2018 VS 2022 VS 2029
  • 6.2 Segment Introduction by Application
    • 6.2.1 Public
    • 6.2.2 Private
  • 6.3 Market Segment by Application
    • 6.3.1 World Oral Vaccine for Human Production by Application (2018-2029)
    • 6.3.2 World Oral Vaccine for Human Production Value by Application (2018-2029)
    • 6.3.3 World Oral Vaccine for Human Average Price by Application (2018-2029)

7 Company Profiles

  • 7.1 Merck
    • 7.1.1 Merck Details
    • 7.1.2 Merck Major Business
    • 7.1.3 Merck Oral Vaccine for Human Product and Services
    • 7.1.4 Merck Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.1.5 Merck Recent Developments/Updates
    • 7.1.6 Merck Competitive Strengths & Weaknesses
  • 7.2 GSK
    • 7.2.1 GSK Details
    • 7.2.2 GSK Major Business
    • 7.2.3 GSK Oral Vaccine for Human Product and Services
    • 7.2.4 GSK Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.2.5 GSK Recent Developments/Updates
    • 7.2.6 GSK Competitive Strengths & Weaknesses
  • 7.3 Sanofi
    • 7.3.1 Sanofi Details
    • 7.3.2 Sanofi Major Business
    • 7.3.3 Sanofi Oral Vaccine for Human Product and Services
    • 7.3.4 Sanofi Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.3.5 Sanofi Recent Developments/Updates
    • 7.3.6 Sanofi Competitive Strengths & Weaknesses
  • 7.4 Lanzhou Institute
    • 7.4.1 Lanzhou Institute Details
    • 7.4.2 Lanzhou Institute Major Business
    • 7.4.3 Lanzhou Institute Oral Vaccine for Human Product and Services
    • 7.4.4 Lanzhou Institute Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.4.5 Lanzhou Institute Recent Developments/Updates
    • 7.4.6 Lanzhou Institute Competitive Strengths & Weaknesses
  • 7.5 Serum Institute
    • 7.5.1 Serum Institute Details
    • 7.5.2 Serum Institute Major Business
    • 7.5.3 Serum Institute Oral Vaccine for Human Product and Services
    • 7.5.4 Serum Institute Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.5.5 Serum Institute Recent Developments/Updates
    • 7.5.6 Serum Institute Competitive Strengths & Weaknesses
  • 7.6 Valneva
    • 7.6.1 Valneva Details
    • 7.6.2 Valneva Major Business
    • 7.6.3 Valneva Oral Vaccine for Human Product and Services
    • 7.6.4 Valneva Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.6.5 Valneva Recent Developments/Updates
    • 7.6.6 Valneva Competitive Strengths & Weaknesses
  • 7.7 Shanghai United Cell
    • 7.7.1 Shanghai United Cell Details
    • 7.7.2 Shanghai United Cell Major Business
    • 7.7.3 Shanghai United Cell Oral Vaccine for Human Product and Services
    • 7.7.4 Shanghai United Cell Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.7.5 Shanghai United Cell Recent Developments/Updates
    • 7.7.6 Shanghai United Cell Competitive Strengths & Weaknesses
  • 7.8 Bibcol
    • 7.8.1 Bibcol Details
    • 7.8.2 Bibcol Major Business
    • 7.8.3 Bibcol Oral Vaccine for Human Product and Services
    • 7.8.4 Bibcol Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.8.5 Bibcol Recent Developments/Updates
    • 7.8.6 Bibcol Competitive Strengths & Weaknesses
  • 7.9 PaxVax
    • 7.9.1 PaxVax Details
    • 7.9.2 PaxVax Major Business
    • 7.9.3 PaxVax Oral Vaccine for Human Product and Services
    • 7.9.4 PaxVax Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.9.5 PaxVax Recent Developments/Updates
    • 7.9.6 PaxVax Competitive Strengths & Weaknesses
  • 7.10 Vabiotech
    • 7.10.1 Vabiotech Details
    • 7.10.2 Vabiotech Major Business
    • 7.10.3 Vabiotech Oral Vaccine for Human Product and Services
    • 7.10.4 Vabiotech Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.10.5 Vabiotech Recent Developments/Updates
    • 7.10.6 Vabiotech Competitive Strengths & Weaknesses
  • 7.11 Tiantan Biological
    • 7.11.1 Tiantan Biological Details
    • 7.11.2 Tiantan Biological Major Business
    • 7.11.3 Tiantan Biological Oral Vaccine for Human Product and Services
    • 7.11.4 Tiantan Biological Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.11.5 Tiantan Biological Recent Developments/Updates
    • 7.11.6 Tiantan Biological Competitive Strengths & Weaknesses
  • 7.12 EuBiologics
    • 7.12.1 EuBiologics Details
    • 7.12.2 EuBiologics Major Business
    • 7.12.3 EuBiologics Oral Vaccine for Human Product and Services
    • 7.12.4 EuBiologics Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.12.5 EuBiologics Recent Developments/Updates
    • 7.12.6 EuBiologics Competitive Strengths & Weaknesses
  • 7.13 Panacea Biotec Ltd
    • 7.13.1 Panacea Biotec Ltd Details
    • 7.13.2 Panacea Biotec Ltd Major Business
    • 7.13.3 Panacea Biotec Ltd Oral Vaccine for Human Product and Services
    • 7.13.4 Panacea Biotec Ltd Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.13.5 Panacea Biotec Ltd Recent Developments/Updates
    • 7.13.6 Panacea Biotec Ltd Competitive Strengths & Weaknesses
  • 7.14 Bio-Med
    • 7.14.1 Bio-Med Details
    • 7.14.2 Bio-Med Major Business
    • 7.14.3 Bio-Med Oral Vaccine for Human Product and Services
    • 7.14.4 Bio-Med Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.14.5 Bio-Med Recent Developments/Updates
    • 7.14.6 Bio-Med Competitive Strengths & Weaknesses
  • 7.15 Halfkin Bio-Pharmaceuticals
    • 7.15.1 Halfkin Bio-Pharmaceuticals Details
    • 7.15.2 Halfkin Bio-Pharmaceuticals Major Business
    • 7.15.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product and Services
    • 7.15.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
    • 7.15.6 Halfkin Bio-Pharmaceuticals Competitive Strengths & Weaknesses

8 Industry Chain Analysis

  • 8.1 Oral Vaccine for Human Industry Chain
  • 8.2 Oral Vaccine for Human Upstream Analysis
    • 8.2.1 Oral Vaccine for Human Core Raw Materials
    • 8.2.2 Main Manufacturers of Oral Vaccine for Human Core Raw Materials
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis
  • 8.5 Oral Vaccine for Human Production Mode
  • 8.6 Oral Vaccine for Human Procurement Model
  • 8.7 Oral Vaccine for Human Industry Sales Model and Sales Channels
    • 8.7.1 Oral Vaccine for Human Sales Model
    • 8.7.2 Oral Vaccine for Human Typical Customers

9 Research Findings and Conclusion

    10 Appendix

    • 10.1 Methodology
    • 10.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Oral Vaccine for Human . Industry analysis & Market Report on Oral Vaccine for Human is a syndicated market report, published as Global Oral Vaccine for Human Supply, Demand and Key Producers, 2023-2029. It is complete Research Study and Industry Analysis of Oral Vaccine for Human market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $4,480.00
    $6,720.00
    $8,960.00
    3,463.04
    5,194.56
    6,926.08
    4,170.88
    6,256.32
    8,341.76
    684,051.20
    1,026,076.80
    1,368,102.40
    378,112.00
    567,168.00
    756,224.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report